Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Announces $12.6 Million in Equity Financings
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Announces Effective Date of Reverse Stock Split
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Provides Anticipated Development Milestones for 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Tickers ASMB
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.